Published in Biochem J on August 15, 2005
The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov (2014) 1.58
Phenotypic analysis of mice lacking the Tmprss2-encoded protease. Mol Cell Biol (2006) 1.44
Regulation of cell surface protease matriptase by HAI2 is essential for placental development, neural tube closure and embryonic survival in mice. Development (2009) 1.38
Inference of disease-related molecular logic from systems-based microarray analysis. PLoS Comput Biol (2006) 1.33
Potent inhibition and global co-localization implicate the transmembrane Kunitz-type serine protease inhibitor hepatocyte growth factor activator inhibitor-2 in the regulation of epithelial matriptase activity. J Biol Chem (2008) 1.31
The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment. Biochem J (2010) 1.27
Loss of matriptase suppression underlies spint1 mutation-associated ichthyosis and postnatal lethality. Am J Pathol (2009) 1.20
c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase. Oncogene (2011) 1.18
Reduced prostasin (CAP1/PRSS8) activity eliminates HAI-1 and HAI-2 deficiency-associated developmental defects by preventing matriptase activation. PLoS Genet (2012) 1.16
Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression. J Biol Chem (2008) 1.14
Membrane-anchored serine proteases in health and disease. Prog Mol Biol Transl Sci (2011) 1.13
Hepatocyte growth factor activator inhibitor-1 has a complex subcellular itinerary. Biochem J (2008) 1.02
Genotype-phenotype correlation in DFNB8/10 families with TMPRSS3 mutations. J Assoc Res Otolaryngol (2011) 0.96
Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther (2009) 0.96
Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model. Int J Cancer (2008) 0.95
Structure of human prostasin, a target for the regulation of hypertension. J Biol Chem (2008) 0.95
Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist. Proc Natl Acad Sci U S A (2007) 0.95
Cd36, a class B scavenger receptor, functions as a monomer to bind acetylated and oxidized low-density lipoproteins. Protein Sci (2007) 0.94
Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting. Am J Clin Exp Urol (2014) 0.91
Plasmin-mediated proteolysis is required for hepatocyte growth factor activation during liver repair. J Biol Chem (2009) 0.88
Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis. Oncotarget (2014) 0.87
Low expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survival. BMC Cancer (2015) 0.85
Cleavage specificity analysis of six type II transmembrane serine proteases (TTSPs) using PICS with proteome-derived peptide libraries. PLoS One (2014) 0.85
Using specificity to strategically target proteases. Bioorg Med Chem (2008) 0.84
Non-syndromic hearing impairment in India: high allelic heterogeneity among mutations in TMPRSS3, TMC1, USHIC, CDH23 and TMIE. PLoS One (2014) 0.84
Functional analysis of a missense mutation in the serine protease inhibitor SPINT2 associated with congenital sodium diarrhea. PLoS One (2014) 0.83
Novel TMPRSS3 variants in Pakistani families with autosomal recessive non-syndromic hearing impairment. Clin Genet (2011) 0.82
Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate. Am J Pathol (2005) 0.82
The serine protease hepsin mediates urinary secretion and polymerisation of Zona Pellucida domain protein uromodulin. Elife (2015) 0.82
Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion. BMC Cancer (2010) 0.81
Allosteric peptide activators of pro-hepatocyte growth factor stimulate Met signaling. J Biol Chem (2010) 0.81
Transcriptome profile analysis reveals specific signatures of pollutants in Atlantic eels. Ecotoxicology (2014) 0.79
Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer. ACS Med Chem Lett (2014) 0.79
Hepatocyte growth factor and the hepatocyte growth factor receptor signalling complex as targets in cancer therapies. Curr Oncol (2007) 0.78
Using LongSAGE to Detect Biomarkers of Cervical Cancer Potentially Amenable to Optical Contrast Agent Labelling. Biomark Insights (2007) 0.78
Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. Oncotarget (2016) 0.77
Hepatitis B virus X protein binding to hepsin promotes C3 production by inducing IL-6 secretion from hepatocytes. Oncotarget (2016) 0.77
Identification of hepsin and protein disulfide isomerase A3 as targets of gelatinolytic action in rat ovarian granulosa cells during the periovulatory period. Biol Reprod (2011) 0.77
In search of a function of Manduca sexta hemolymph protease-1 in the innate immune system. Insect Biochem Mol Biol (2016) 0.76
Design and Synthesis of Nonpeptide Inhibitors of Hepatocyte Growth Factor Activation. ACS Med Chem Lett (2015) 0.76
Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment. Cancers (Basel) (2017) 0.75
High Hepsin expression predicts poor prognosis in Gastric Cancer. Sci Rep (2016) 0.75
SERPINB12 Is a Slow-Binding Inhibitor of Granzyme A and Hepsin. Biochemistry (2015) 0.75
Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion. Oncogene (2015) 0.75
Urokinase-controlled tumor penetrating peptide. J Control Release (2016) 0.75
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
Delineation of prognostic biomarkers in prostate cancer. Nature (2001) 12.25
Rapid automated molecular replacement by evolutionary search. Acta Crystallogr D Biol Crystallogr (1999) 8.97
Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 7.29
Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res (2001) 6.73
Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res (2001) 4.51
Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer (2002) 3.89
Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res (2001) 3.45
Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc Natl Acad Sci U S A (2000) 3.06
Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst (2001) 2.83
Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem (2000) 2.50
Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin. Nat Biotechnol (2000) 2.49
Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem (2000) 2.47
Limited N-terminal sequence analysis. Methods Enzymol (1990) 2.40
Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev (2003) 2.39
A statistical method for identifying differential gene-gene co-expression patterns. Bioinformatics (2004) 2.23
Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem (1995) 2.06
Substrate phage: selection of protease substrates by monovalent phage display. Science (1993) 2.04
Hepsin promotes prostate cancer progression and metastasis. Cancer Cell (2004) 1.89
A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells. Biochemistry (1988) 1.89
Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol (2001) 1.87
The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res (2004) 1.80
Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J (2004) 1.79
The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem (1994) 1.65
Molecular cloning and sequence analysis of the cDNA for a human serine protease reponsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J Biol Chem (1993) 1.57
Three-dimensional structure of proteins determined by molecular dynamics with interproton distance restraints: application to crambin. Proc Natl Acad Sci U S A (1986) 1.52
Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer (2004) 1.47
Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem (1997) 1.45
Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res (2002) 1.44
Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett (2005) 1.34
Biochemical characterization of prostasin, a channel activating protease. Biochem Biophys Res Commun (2004) 1.30
Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1. J Biol Chem (2003) 1.29
Affinity purification of recombinant trypsinogen using immobilized ecotin. Protein Expr Purif (1998) 1.27
Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res (1997) 1.23
Generation and characterization of mice deficient in hepsin, a hepatic transmembrane serine protease. J Clin Invest (1998) 1.21
Crystal structure of enteropeptidase light chain complexed with an analog of the trypsinogen activation peptide. J Mol Biol (1999) 1.19
Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev (2003) 1.19
Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B. J Mol Biol (2005) 1.14
Activation of hepatocyte growth factor by two homologous proteases, blood-coagulation factor XIIa and hepatocyte growth factor activator. Eur J Biochem (1995) 1.14
Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol (2004) 1.11
Hepsin, a cell membrane-associated protease. Characterization, tissue distribution, and gene localization. J Biol Chem (1991) 1.10
Hepsin, a putative membrane-associated serine protease, activates human factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation. J Biol Chem (1995) 1.09
Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer. J Urol (2003) 1.08
HEPSIN inhibits cell growth/invasion in prostate cancer cells. Cancer Res (2002) 1.07
Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator. J Biol Chem (1996) 1.02
Type II transmembrane serine proteases. Curr Top Dev Biol (2003) 1.01
Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries. Prostate (2005) 0.99
Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa. J Biol Chem (2002) 0.98
Gene targeting in hemostasis. Hepsin. Front Biosci (2001) 0.98
Banking of fresh-frozen prostate tissue: methods, validation and use. BJU Int (2003) 0.98
The structure of the extracellular region of human hepsin reveals a serine protease domain and a novel scavenger receptor cysteine-rich (SRCR) domain. Structure (2003) 0.96
Epidemiology and management of venous thromboembolism in patients with cancer. Thromb Res (2003) 0.95
Hepsin paradox reveals unexpected complexity of metastatic process. Cell Cycle (2004) 0.93
Definition of the extended substrate specificity determinants for beta-tryptases I and II. J Biol Chem (2001) 0.91
Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells. Int J Cancer (1999) 0.90
Mice deficient in hepsin, a serine protease, exhibit normal embryogenesis and unchanged hepatocyte regeneration ability. Thromb Haemost (2000) 0.89
Hepsin, a putative cell-surface serine protease, is required for mammalian cell growth. Proc Natl Acad Sci U S A (1993) 0.88
Identification and cloning of the membrane-associated serine protease, hepsin, from mouse preimplantation embryos. J Biol Chem (1997) 0.88
Expression of the factor VII activating protease, hepsin, in situ in renal cell carcinoma. Thromb Haemost (1998) 0.87
Identification and characterization of hepsin/-TM, a non-transmembrane hepsin isoform. Biochim Biophys Acta (2004) 0.84
Purification and characterization of hepsin from rat liver microsomes. Biochim Biophys Acta (1997) 0.83
Molecular profiling of prostate cancer. Curr Urol Rep (2004) 0.82
Hepsin. Methods Enzymol (1994) 0.81
Comparison of hepatocyte growth factor levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts. Int J Gynecol Cancer (2004) 0.80
A novel heterocyclic compound: catena-poly[[[diaquasodium(I)]-di-mu-aqua] hemi(1,5-dihydroxy-4,8,9-trioxa-2,6-diazabicyclo[3.3.1]nona-2,6-diene-3,7-diolate)]. Acta Crystallogr C (2007) 65.39
Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A (2007) 13.58
The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med (2007) 13.39
The 2005 World Health Organization reevaluation of human and Mammalian toxic equivalency factors for dioxins and dioxin-like compounds. Toxicol Sci (2006) 6.86
Global landscape of HIV-human protein complexes. Nature (2011) 3.70
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A (2009) 3.39
Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection. Nature (2011) 2.71
Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet (2002) 2.23
Local protease signaling contributes to neural tube closure in the mouse embryo. Dev Cell (2010) 2.19
TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol Cell (2002) 2.18
Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J Biol Chem (2006) 2.05
Trapping moving targets with small molecules. Science (2009) 1.86
Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling. J Biol Chem (2003) 1.85
Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. Proc Natl Acad Sci U S A (2005) 1.82
Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A (2012) 1.80
Interaction of the S-phase cyclin Clb5 with an "RXL" docking sequence in the initiator protein Orc6 provides an origin-localized replication control switch. Genes Dev (2004) 1.79
Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell (2003) 1.76
Mycobacterium tuberculosis MycP1 protease plays a dual role in regulation of ESX-1 secretion and virulence. Cell Host Microbe (2010) 1.76
T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem (2002) 1.75
G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway. Proc Natl Acad Sci U S A (2005) 1.75
Engineering of a macromolecular scaffold to develop specific protease inhibitors. Nat Biotechnol (2003) 1.73
Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene (2005) 1.68
Systems-based design of bi-ligand inhibitors of oxidoreductases: filling the chemical proteomic toolbox. Chem Biol (2004) 1.52
Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway. Proc Natl Acad Sci U S A (2007) 1.52
Essential role of a GXXXG motif for membrane channel formation by Helicobacter pylori vacuolating toxin. J Biol Chem (2003) 1.50
Canonical wnt signaling is required for pancreatic carcinogenesis. Cancer Res (2013) 1.49
Multiclass cancer classification and biomarker discovery using GA-based algorithms. Bioinformatics (2005) 1.45
Heterogeneity among Helicobacter pylori strains in expression of the outer membrane protein BabA. Infect Immun (2004) 1.45
Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice. EMBO J (2006) 1.42
A multi-enzyme cascade of hemoglobin proteolysis in the intestine of blood-feeding hookworms. J Biol Chem (2004) 1.41
NK-cell and B-cell deficiency with a thymic mass. N Engl J Med (2011) 1.39
Two-dimensional infrared spectroscopy reveals the complex behaviour of an amyloid fibril inhibitor. Nat Chem (2012) 1.39
SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase. J Med Chem (2006) 1.35
Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res (2010) 1.32
The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine (2008) 1.32
Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences. J Biol Chem (2006) 1.31
Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem J (2003) 1.29
Molecular basis of PCSK9 function. Atherosclerosis (2008) 1.29
Expedient solid-phase synthesis of fluorogenic protease substrates using the 7-amino-4-carbamoylmethylcoumarin (ACC) fluorophore. J Org Chem (2002) 1.26
Fabs enable single particle cryoEM studies of small proteins. Structure (2012) 1.25
Continuous imaging of plasmon rulers in live cells reveals early-stage caspase-3 activation at the single-molecule level. Proc Natl Acad Sci U S A (2009) 1.25
Methyl groups as probes for proteins and complexes in in-cell NMR experiments. J Am Chem Soc (2004) 1.23
Cercarial elastase is encoded by a functionally conserved gene family across multiple species of schistosomes. J Biol Chem (2002) 1.22
Elimination of 13Calpha splitting in protein NMR spectra by deconvolution with maximum entropy reconstruction. J Am Chem Soc (2003) 1.21
Inhibition of a viral enzyme by a small-molecule dimer disruptor. Nat Chem Biol (2009) 1.21
PRC17, a novel oncogene encoding a Rab GTPase-activating protein, is amplified in prostate cancer. Cancer Res (2002) 1.20
Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. Chem Biol (2011) 1.20
Mechanism of IAPP amyloid fibril formation involves an intermediate with a transient β-sheet. Proc Natl Acad Sci U S A (2013) 1.20
Structural and functional relationships in the virulence-associated cathepsin L proteases of the parasitic liver fluke, Fasciola hepatica. J Biol Chem (2007) 1.19
Vinyl sulfones as antiparasitic agents and a structural basis for drug design. J Biol Chem (2009) 1.18
Molecular basis of sphingosine kinase 1 substrate recognition and catalysis. Structure (2013) 1.18
Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease. J Virol (2002) 1.17
Isotope-coded and affinity-tagged cross-linking (ICATXL): an efficient strategy to probe protein interaction surfaces. J Am Chem Soc (2006) 1.17
Oncogenic potential of TASK3 (Kcnk9) depends on K+ channel function. Proc Natl Acad Sci U S A (2003) 1.17
Genome-wide transcriptional profiling in a histidine kinase mutant of Helicobacter pylori identifies members of a regulon. J Bacteriol (2002) 1.16
Granzyme B proteolyzes receptors important to proliferation and survival, tipping the balance toward apoptosis. J Biol Chem (2006) 1.16
Global identification of peptidase specificity by multiplex substrate profiling. Nat Methods (2012) 1.14
IRAK-4 inhibitors for inflammation. Curr Top Med Chem (2009) 1.13
Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies. Biochemistry (2003) 1.12
Selective chemical functional probes of granzymes A and B reveal granzyme B is a major effector of natural killer cell-mediated lysis of target cells. Chem Biol (2005) 1.12
Quantitative identification of the protonation state of histidines in vitro and in vivo. Biochemistry (2003) 1.11
Selective inhibition of the collagenolytic activity of human cathepsin K by altering its S2 subsite specificity. Biochemistry (2002) 1.10
Synthesis and antimicrobial activities of 7-O-modified genistein derivatives. Eur J Med Chem (2007) 1.10
The mechanism of inhibition of antibody-based inhibitors of membrane-type serine protease 1 (MT-SP1). J Mol Biol (2007) 1.10
Structure of an Fab-protease complex reveals a highly specific non-canonical mechanism of inhibition. J Mol Biol (2008) 1.09
Molecular signatures of prostate stem cells reveal novel signaling pathways and provide insights into prostate cancer. PLoS One (2009) 1.08
Th1 cells regulate hematopoietic progenitor cell homeostasis by production of oncostatin M. Immunity (2002) 1.08
Use of recombinant Entamoeba histolytica cysteine proteinase 1 to identify a potent inhibitor of amebic invasion in a human colonic model. Eukaryot Cell (2007) 1.07
A parasite cysteine protease is key to host protein degradation and iron acquisition. J Biol Chem (2008) 1.06
Ion mobility spectrometry-mass spectrometry defines the oligomeric intermediates in amylin amyloid formation and the mode of action of inhibitors. J Am Chem Soc (2013) 1.06
The periplasmic serine protease inhibitor ecotin protects bacteria against neutrophil elastase. Biochem J (2004) 1.05
Morin hydrate inhibits amyloid formation by islet amyloid polypeptide and disaggregates amyloid fibers. Protein Sci (2012) 1.05
Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration. J Biol Chem (2010) 1.04
The oligomeric structure of human granzyme A is a determinant of its extended substrate specificity. Nat Struct Biol (2003) 1.04
Prediction of protease substrates using sequence and structure features. Bioinformatics (2010) 1.04
Communication between the active sites and dimer interface of a herpesvirus protease revealed by a transition-state inhibitor. Proc Natl Acad Sci U S A (2004) 1.03
Systems toxicology and the Chemical Effects in Biological Systems (CEBS) knowledge base. EHP Toxicogenomics (2003) 1.03
GPS-Prot: a web-based visualization platform for integrating host-pathogen interaction data. BMC Bioinformatics (2011) 1.03
A novel Entamoeba histolytica cysteine proteinase, EhCP4, is key for invasive amebiasis and a therapeutic target. J Biol Chem (2010) 1.03
Deamidation accelerates amyloid formation and alters amylin fiber structure. J Am Chem Soc (2012) 1.03
Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells. Clin Cancer Res (2012) 1.02
Hemoglobin cleavage site-specificity of the Plasmodium falciparum cysteine proteases falcipain-2 and falcipain-3. PLoS One (2009) 1.02
Critical role of amino acid 23 in mediating activity and specificity of vinckepain-2, a papain-family cysteine protease of rodent malaria parasites. Biochem J (2002) 1.02
IrAE: an asparaginyl endopeptidase (legumain) in the gut of the hard tick Ixodes ricinus. Int J Parasitol (2007) 1.01
Obliteration of alpha-melanocyte-stimulating hormone derived from POMC in pituitary and brains of PC2-deficient mice. J Neurochem (2003) 1.00
Global substrate profiling of proteases in human neutrophil extracellular traps reveals consensus motif predominantly contributed by elastase. PLoS One (2013) 1.00
Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries. Prostate (2005) 0.99
Palladium-catalyzed intermolecular coupling of aryl chlorides and sulfonamides under microwave irradiation. Org Lett (2003) 0.99
Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7. Biol Chem (2008) 0.99